Treatment with Verzenio plus endocrine therapy demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to endocrine therapy alone In the seven-year ...

Lilly's CYRAMZA (ramucirumab) significantly improved overall survival in phase 3 non-small cell lung cancer study. Results from the REVEL trial were published in The Lancet and also presented at ASCO ...

(Reuters) – Eli Lilly and Co’s stomach cancer drug ramucirumab met its primary goal of improving overall survival in a late stage-study, extending the lives of patients for more than a month longer ...

Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvant HR+, HER2−, high-risk early breast cancer. Seven-year results from the ...